Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019
暂无分享,去创建一个
S. Billová | J. Szabó | I. Mareković | V. Adámková | B. Możejko-Pastewka | L. Pojnar | S. Horvat Herceg | A. Kuraieva
[1] S. Billová,et al. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018. , 2021, Diagnostic microbiology and infectious disease.
[2] S. Beatson,et al. Antimicrobial Resistance in ESKAPE Pathogens , 2020, Clinical Microbiology Reviews.
[3] Sameer S. Kadri,et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] K. Kazmierczak,et al. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012–15 , 2018, The Journal of antimicrobial chemotherapy.
[5] K. Kazmierczak,et al. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15 , 2018, The Journal of antimicrobial chemotherapy.
[6] Paul Newell,et al. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Y. Carmeli,et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. , 2016, The Lancet. Infectious diseases.
[8] K. Kazmierczak,et al. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014) , 2016, Antimicrobial Agents and Chemotherapy.
[9] J. Mazuski,et al. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] R. Bonomo,et al. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases. , 2015, Diagnostic microbiology and infectious disease.
[11] K. Kazmierczak,et al. Trends in Susceptibility of Escherichia coli from Intra-Abdominal Infections to Ertapenem and Comparators in the United States According to Data from the SMART Program, 2009 to 2013 , 2015, Antimicrobial Agents and Chemotherapy.
[12] A. Girard,et al. In Vitro Antibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases , 2015, Antimicrobial Agents and Chemotherapy.
[13] B. Glick,et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. , 2019, Biotechnology advances.
[14] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .